<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978314</url>
  </required_header>
  <id_info>
    <org_study_id>FAST mGFR -002</org_study_id>
    <secondary_id>1R44DK093274-01</secondary_id>
    <nct_id>NCT01978314</nct_id>
  </id_info>
  <brief_title>FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.</brief_title>
  <official_title>A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) Test™ in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FAST BioMedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>FAST BioMedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single site study designed to evaluate the FAST mGFR Test™ in healthy adult
      volunteers, patients with varying degrees of chronic kidney disease (CKD), and patients with
      acute kidney injury (AKI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A rapid and accurate measurement of glomerular filtration rate (GFR) is important in acute
      kidney injury (AKI) and chronic kidney disease (CKD) for assessment of impairment, diagnosis,
      and prompt treatment. FAST BioMedical is an emerging technology company whose mission is to
      quantify clinically meaning ful physiological parameters that have been difficult or
      impossible to measure. GFR is the most clinically relevant metric for understanding renal
      function, as it is the rate by which the kidney is able to filter waste products in the
      bloodstream. The FAST mGFR is for direct measurement of GFR that relies on reading the ratio
      of fluorescent markers attached to different size dextran molecules introduced into the
      bloodstream. The test is intended as an adjunct to current methods utilized to assess kidney
      function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This pilot study was a prospective, open-label, single site study designed to evaluate the safety of the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of renal impairment and hemodynamically stable AKI.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>Baseline through day 22</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>Baseline through day 22</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>Cmax = maximum observed concentration occurring at Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>Tmax = time of maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>AUClast = area under the concentration-time curve (time 0 to last sample with a quantifiable measurable concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCall of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>AUCall = area under the concentration-time curve (time 0 to last scheduled sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>AUCinf = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2, z of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>T1/2 = terminal half-life = ln(2)/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>Vz = volume of distribution based upon terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>Vss = volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>CL = total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>Cmax/Dose = maximum observed concentration occurring at Tmax/Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</measure>
    <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
    <description>AUCinf/Dose = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)/Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Results From the GFR Determined From the FAST VFI™ to GFR Derived From Iohexol Clearance Methods.</measure>
    <time_frame>Baseline through Day 22</time_frame>
    <description>This analysis will compare estimates of kidney function derived from the results of FAST VFI™ to those derived through conventional Iohexol clearance methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Correlation Between FAST's Plasma Volume Method and Standard Clinical Estimates of Plasma Volume.</measure>
    <time_frame>Baseline through day 22</time_frame>
    <description>This analysis will compare estimates of plasma volume derived by FAST's plasma volume method with that derived using the conventional Nadler's Formula for plasma volume.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>75 mg / 6 mL VFI™</intervention_name>
    <description>Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Groups 1-3:

          -  Female subjects: women must have a negative urine pregnancy test at screening and
             before dosing on Visit 2 and be either confirmed by the Investigator to be infertile
             or using a reliable method of contraception Male subjects: reproductively active men
             must agree to either practice abstinence or utilize adequate contraception.

          -  Ages 19 to 75

          -  Subject's screening must fall into one of the available categories of estimated
             glomerular filtration rate (eGFR) renal function: ≥ 60 mL/min for stage normal
             function; 30-59 mL/min for stage 3, moderate CKD; 15-29 mL/min for stage 4, severe
             CKD,

          -  Patients must not be on inotropes or vasopressors, and must be absent of significant
             hemodynamic instabilities.

          -  Patients must have ceased use of the following:

               -  nonsteroidal anti-inflammatory drugs - 6 days prior,

               -  herbal supplements - 6 days prior to testing and

               -  cimetidine and trimethoprim - 14 days prior to testing.

          -  Ability to comply with study conditions

        Inclusion Criteria for Group 4:

        - Female subjects; women must have a negative urine pregnancy test at screening and before
        dosing on Visit 2 and be either confirmed by the Investigator to be infertile or using a
        reliable method of contraception.

        Male subjects: reproductively active men must agree to either practice abstinence or
        utilize adequate contraception.

          -  Ages 19 to 75

          -  For cohort 4: patients diagnosed with [either RIFLE stage I or Acute Kidney Injury
             Network (AKIN) stage 2 AKI]

          -  Patients must not be on inotropes or vasopressors, and must be absent of significant
             hemodynamic instabilities.

          -  Patients must be without evidence of clinically significant liver dysfunction

          -  Ability to comply with study conditions

        Exclusion Criteria for Groups 1-3:

          -  Positive history of any clinically significant allergic or negative reactions, side
             effects, or anaphylaxis to sulfa, iodine, dyes, shellfish, isotopes or dextran
             molecules

          -  Previous history of nephrectomy or kidney transplant

          -  A body weight below 40kg

          -  A body mass index &lt;17 or &gt;40

          -  Subjects using Coumadin (Warfarin) who have an INR &gt;4 at Screening or pre-dose on
             Visit 2

          -  Past history of liver disease or screening Liver Function tests which exceed 1.5 times
             the upper limit of normal or an albumin of &lt; 2mg/dl.

          -  Clinically significant illness within 4 weeks or a clinically significant infection
             within 4 weeks of screening

          -  Received blood, donated blood, have clinically significant on-going bleeding, changing
             haemoglobin, or experienced significant blood loss within 2 weeks of dosing

          -  Subjects with significant abnormal findings upon physical examination, vital signs,
             ECG, or clinical laboratory results at Screening

          -  Subjects with a supine blood pressure after resting for at least 5 minutes outside the
             90-145 (systolic) or mmHg or 50-95 mmHg (diastolic) range

          -  Subjects with a supine (ECG) heart rate outside 45-105 beats/min after resting for at
             least 5 minutes.

          -  Subjects with a known or suspected history of drug or alcohol misuse within 6 months
             prior to screening, subjects who have consumed alcohol within 48 hours of dosing, or
             subjects who the Investigator believes to be unfit to participate in the study due to
             abuse of illegal or controlled substances.

          -  Subjects who had a positive result for Hepatitis B surface antigen (HBsAg) or
             Hepatitis C virus antibody (HCVAb) screen.

          -  Subjects who have been diagnosed with acquired immune deficiency syndrome (AIDS), or
             test positive for human immunodeficiency virus (HIV).

          -  Subjects who participated in another clinical trial less than 1 month prior to dosing,
             or who are currently enrolled in another clinical trial.

          -  Subjects who have any condition that:

               -  Would make him/her, in the opinion of the Investigator, unsuitable for the study

               -  Whose condition is likely to deteriorate

               -  Who, in the opinion of the Investigator, is not likely to complete the study for
                  any reason

        Exclusion Criteria for Group 4:

          -  Positive history of any clinically significant allergic or negative reactions, side
             effects, or anaphylaxis to sulfa, iodine, dyes, shellfish, isotopes or dextran
             molecules

          -  Previous history of nephrectomy or kidney transplant

          -  A body weight below 40kg

          -  A body mass index &lt;17 or &gt;40

          -  Current use of prescribed anticoagulants

          -  Past history of liver disease or screening Liver Function tests which exceed 1.5 times
             the upper limit of normal or an albumin of &lt; 2mg/dl.

          -  Received blood, donated blood, have clinically significant on-going bleeding, changing
             haemoglobin, or experienced significant blood loss within 2 weeks of dosing

          -  Subjects with a supine blood pressure after resting for at least 5 minutes outside the
             90-145 (systolic) or mmHg or 50-95 mmHg (diastolic) range

          -  Subjects with a supine (ECG) heart rate outside 45-105 beats/min after resting for at
             least 5 minutes.

          -  Subjects with a known or suspected history of drug or alcohol abuse within 6 months
             prior to admission, who have a positive drug test or alcohol test, or who have
             consumed alcohol within 24 of testing

          -  Subjects who had a positive result for Hepatitis B surface antigen (HBsAg) or
             Hepatitis C virus antibody (HCVAb) screen.

          -  Subjects who have been diagnosed with acquired immune deficiency syndrome (AIDS), or
             test positive for human immunodeficiency virus (HIV).

          -  Subjects who participated in another clinical trial less than 1 month prior to dosing,
             or who are currently enrolled in another clinical trial.

          -  Subjects who have any condition that:

               -  Would make him/her, in the opinion of the Investigator, unsuitable for the study

               -  Whose condition is likely to deteriorate

               -  Who, in the opinion of the Investigator, is not likely to complete the study for
                  any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana V Rizk, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama Birmingham, 205-934-9509, drizk@uab.edu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham, Division of Nephrology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wang E, Meier DJ, Sandoval RM, Von Hendy-Willson VE, Pressler BM, Bunch RM, Alloosh M, Sturek MS, Schwartz GJ, Molitoris BA. A portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals. Kidney Int. 2012 Jan;81(1):112-7. doi: 10.1038/ki.2011.294. Epub 2011 Aug 31.</citation>
    <PMID>21881552</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <results_first_submitted>February 21, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Acute Kidney Injury</keyword>
  <keyword>AKI</keyword>
  <keyword>CKD</keyword>
  <keyword>Plasma Volume</keyword>
  <keyword>GFR</keyword>
  <keyword>Glomerular Filtration Rate</keyword>
  <keyword>Blood volume</keyword>
  <keyword>mGFR</keyword>
  <keyword>measured GFR</keyword>
  <keyword>kidney biomarker</keyword>
  <keyword>renal disease</keyword>
  <keyword>renal biomarker</keyword>
  <keyword>Renal function</keyword>
  <keyword>kidney function</keyword>
  <keyword>organ function</keyword>
  <keyword>kidney monitor</keyword>
  <keyword>kidney device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>eGFR renal function ≥60 mL/min for normal function</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>eGFR renal function ≥60 mL/min for normal function</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Estimated GFR (mL/min)
≥60 mL/min/1.73m2 BSA</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Estimated GFR (mL/min) 30-59 mL/min/1.73m2 BSA</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Estimated GFR (mL/min) 15-29 mL/min/1.73m2 BSA</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Estimated GFR (mL/min) sCr: ≥2-fold increase or eGFR: &gt;50% decrease compared to baseline</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5</title>
          <description>Estimated GFR (mL/min)
≥60 mL/min/1.73m2 BSA</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="1"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="5.19"/>
                    <measurement group_id="B2" value="56.6" spread="7.03"/>
                    <measurement group_id="B3" value="55.6" spread="17.74"/>
                    <measurement group_id="B4" value="63.0" spread="0"/>
                    <measurement group_id="B5" value="31.8" spread="14.10"/>
                    <measurement group_id="B6" value="46.98" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
        <time_frame>Baseline through day 22</time_frame>
        <population>Intent-to-treat subject population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>sCr: ≥2-fold increase or eGFR: &gt;50% decrease compared to baseline</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
          <population>Intent-to-treat subject population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
        <time_frame>Baseline through day 22</time_frame>
        <population>Intent-to-treat subject population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>sCr: ≥2-fold increase or eGFR: &gt;50% decrease compared to baseline</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product or investigational medical device.</description>
          <population>Intent-to-treat subject population</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of treatment-emergent adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of serious treatment-emergent adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>Cmax = maximum observed concentration occurring at Tmax</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>Cmax = maximum observed concentration occurring at Tmax</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8949" spread="1350"/>
                    <measurement group_id="O3" value="9725" spread="1847"/>
                    <measurement group_id="O5" value="9336" spread="1553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9569" spread="1809"/>
                    <measurement group_id="O3" value="10906" spread="2307"/>
                    <measurement group_id="O5" value="12663" spread="2680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>Tmax = time of maximum observed concentration</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>Tmax = time of maximum observed concentration</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.281" spread="0.0884"/>
                    <measurement group_id="O3" value="0.273" spread="0.0947"/>
                    <measurement group_id="O5" value="0.25" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.33" spread="8.16"/>
                    <measurement group_id="O3" value="0.335" spread="0.27"/>
                    <measurement group_id="O5" value="2.64" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>AUClast = area under the concentration-time curve (time 0 to last sample with a quantifiable measurable concentration)</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>AUClast = area under the concentration-time curve (time 0 to last sample with a quantifiable measurable concentration)</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>ng∙hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="37594" spread="12938"/>
                    <measurement group_id="O3" value="74317" spread="27069"/>
                    <measurement group_id="O5" value="18681" spread="2066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1701850" spread="276886"/>
                    <measurement group_id="O3" value="1642731" spread="443350"/>
                    <measurement group_id="O5" value="1710348" spread="355518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCall of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>AUCall = area under the concentration-time curve (time 0 to last scheduled sample)</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>AUCall of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>AUCall = area under the concentration-time curve (time 0 to last scheduled sample)</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>ng∙hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="42462" spread="12128"/>
                    <measurement group_id="O3" value="80058" spread="25030"/>
                    <measurement group_id="O5" value="19924" spread="2441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1701850" spread="276886"/>
                    <measurement group_id="O3" value="1642731" spread="443350"/>
                    <measurement group_id="O5" value="1710348" spread="355518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>AUCinf = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>AUCinf = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>ng∙hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="38844" spread="12960"/>
                    <measurement group_id="O3" value="76554" spread="26430"/>
                    <measurement group_id="O5" value="19127" spread="2107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1821296" spread="302728"/>
                    <measurement group_id="O3" value="1756948" spread="503557"/>
                    <measurement group_id="O5" value="1755162" spread="366071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2, z of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>T1/2 = terminal half-life = ln(2)/λz</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2, z of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>T1/2 = terminal half-life = ln(2)/λz</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="9.48" spread="4.28"/>
                    <measurement group_id="O3" value="18.3" spread="12.6"/>
                    <measurement group_id="O5" value="5.64" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="123" spread="38.9"/>
                    <measurement group_id="O3" value="125" spread="32.8"/>
                    <measurement group_id="O5" value="90.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>Vz = volume of distribution based upon terminal phase</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>Vz of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>Vz = volume of distribution based upon terminal phase</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8343" spread="1733"/>
                    <measurement group_id="O3" value="7907" spread="2613"/>
                    <measurement group_id="O5" value="11451" spread="3430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1177" spread="293"/>
                    <measurement group_id="O3" value="1384" spread="644"/>
                    <measurement group_id="O5" value="1018" spread="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vss of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>Vss = volume of distribution at steady state</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>Vss of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>Vss = volume of distribution at steady state</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>mL/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5430" spread="781"/>
                    <measurement group_id="O3" value="5464" spread="1425"/>
                    <measurement group_id="O5" value="6599" spread="4289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1039" spread="299"/>
                    <measurement group_id="O3" value="1132" spread="274"/>
                    <measurement group_id="O5" value="937" spread="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>CL = total body clearance</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>CL of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>CL = total body clearance</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>mL/hr/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="677" spread="190"/>
                    <measurement group_id="O3" value="143" spread="39.5"/>
                    <measurement group_id="O5" value="1404" spread="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.82" spread="1.26"/>
                    <measurement group_id="O3" value="7.65" spread="2.67"/>
                    <measurement group_id="O5" value="7.74" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>Cmax/Dose = maximum observed concentration occurring at Tmax/Dose</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>Cmax/Dose = maximum observed concentration occurring at Tmax/Dose</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>[(ng/mL)/(mg/m^2)]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="369" spread="43.1"/>
                    <measurement group_id="O3" value="73.8" spread="18.7"/>
                    <measurement group_id="O5" value="354" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="787" spread="125"/>
                    <measurement group_id="O3" value="877" spread="135"/>
                    <measurement group_id="O5" value="956" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCinf/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
        <description>AUCinf/Dose = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)/Dose</description>
        <time_frame>PK parameters were evaluated using samples collected pre and post dose at day 2, as well as post dose on days 4, 8, 15, 22.</time_frame>
        <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol</description>
          </group>
        </group_list>
        <measure>
          <title>AUCinf/Dose of FD001 and FD003 Following Administration of VFI™ in Patients With Varying Degrees of Kidney Function</title>
          <description>AUCinf/Dose = area under the concentration-time curve (time 0 extrapolated to infinity based on the last observed concentration)/Dose</description>
          <population>Intent-to-treat subject population analyzed. PK was not evaluated in Cohort 1 due to a contamination problem caused by the sample collection catheter used in this cohort. In addition, PK data was not collected for the single subject dosed in Group 4.</population>
          <units>[(ng∙hr/mL)/(mg/m^2)]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FD001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1641" spread="590"/>
                    <measurement group_id="O3" value="1071" spread="34.6"/>
                    <measurement group_id="O5" value="731" spread="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FD003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="150220" spread="22006"/>
                    <measurement group_id="O3" value="141337" spread="35933"/>
                    <measurement group_id="O5" value="131599" spread="19656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Results From the GFR Determined From the FAST VFI™ to GFR Derived From Iohexol Clearance Methods.</title>
        <description>This analysis will compare estimates of kidney function derived from the results of FAST VFI™ to those derived through conventional Iohexol clearance methods.</description>
        <time_frame>Baseline through Day 22</time_frame>
        <population>The subject in Cohort 4 did not receive Iohexol. One subject in Cohort 5 withdrew from the study before receiving Iohexol. Samples were missing for 1 subject in each of Cohorts 1 and 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Results From the GFR Determined From the FAST VFI™ to GFR Derived From Iohexol Clearance Methods.</title>
          <description>This analysis will compare estimates of kidney function derived from the results of FAST VFI™ to those derived through conventional Iohexol clearance methods.</description>
          <population>The subject in Cohort 4 did not receive Iohexol. One subject in Cohort 5 withdrew from the study before receiving Iohexol. Samples were missing for 1 subject in each of Cohorts 1 and 3.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VFI mGFR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.20" spread="16.967"/>
                    <measurement group_id="O2" value="42.89" spread="5.810"/>
                    <measurement group_id="O3" value="30.17" spread="5.174"/>
                    <measurement group_id="O4" value="70.86" spread="0"/>
                    <measurement group_id="O5" value="65.17" spread="10.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Iohexol GFR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.25" spread="9.898"/>
                    <measurement group_id="O2" value="57.52" spread="15.816"/>
                    <measurement group_id="O3" value="31.76" spread="8.340"/>
                    <measurement group_id="O5" value="110.52" spread="12.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Correlation Between FAST’s Plasma Volume Method and Standard Clinical Estimates of Plasma Volume.</title>
        <description>This analysis will compare estimates of plasma volume derived by FAST's plasma volume method with that derived using the conventional Nadler's Formula for plasma volume.</description>
        <time_frame>Baseline through day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
75 mg / 6 mL VFI™: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
75 mg / 6 mL VFI™: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
75 mg / 6 mL VFI™: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
75 mg / 6 mL VFI™: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
75 mg / 6 mL VFI™: Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Correlation Between FAST’s Plasma Volume Method and Standard Clinical Estimates of Plasma Volume.</title>
          <description>This analysis will compare estimates of plasma volume derived by FAST's plasma volume method with that derived using the conventional Nadler's Formula for plasma volume.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FAST Plasma Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3251.088" spread="452.6180"/>
                    <measurement group_id="O2" value="2926.941" spread="568.1260"/>
                    <measurement group_id="O3" value="2816.244" spread="533.7910"/>
                    <measurement group_id="O4" value="6046.770" spread="0"/>
                    <measurement group_id="O5" value="2415.950" spread="569.1105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nadler's Formula Plasma Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2859.671" spread="313.2253"/>
                    <measurement group_id="O2" value="3103.431" spread="443.1221"/>
                    <measurement group_id="O3" value="3150.045" spread="393.3610"/>
                    <measurement group_id="O4" value="5297.820" spread="0"/>
                    <measurement group_id="O5" value="2805.234" spread="412.2505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through day 22.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>eGFR renal function ≥60 mL/min for normal function</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>eGFR renal function 30-59 mL/min for stage 3, moderate CKD</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>eGFR renal function 15-29 mL/min for stage 4, severe CKD</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4</title>
          <description>a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5</title>
          <description>eGFR renal function ≥60 mL/min for normal function</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Conjunctival Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Miosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea Versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood Potassium Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Liver Palpable Subcostal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Too restrictive entry criteria for enrollment into the AKI cohort and the expiry of the clinical VFI led to a decision, in consultation with FDA, to stop the study prematurely.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dana Victor Rizk, M.D.</name_or_title>
      <organization>University of Alabama, Birmingham</organization>
      <email>drizk@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

